A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B‐cell non‐Hodgkin lymphoma: A Wisconsin Oncology Network study

201537 citationsJournal Articlebronze Open Access

Authors

Timothy S. Fenske · Medical College of Wisconsin

Namrata Mahendra Shah · Medical College of Wisconsin

Kyung Mann Kim · University of Wisconsin Carbone Cancer Center

Sandeep Saha · University of Wisconsin–Madison

Chong Zhang · University of Wisconsin–Madison

Arielle Baim · Medical College of Wisconsin

John P. Farnen

Abstract

The current results demonstrate that the combination of a mammalian target of rapamycin inhibitor and a proteasome inhibitor is safe and has activity in patients with heavily pretreated B-cell NHL. Further studies with this combination are warranted in specific subtypes of NHL.

Topics & Keywords

Multiple Myeloma Research and Treatments Lymphoma Diagnosis and Treatment Protein Degradation and Inhibitors

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer

Volume 121, Issue 19, pp. 3465-3471

DOI: 10.1002/cncr.29502

Field-Weighted Citation Impact: 4.19